Literature DB >> 10811331

Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease.

A V Indaram1, V Visvalingam, M Locke, S Bank.   

Abstract

OBJECTIVE: We measured the mucosal levels of interleukin 1beta (IL-1beta), IL-2, IL-6, and IL-8 in affected segments of radiation-induced proctosigmoiditis and compared these with the levels in normal controls and inflammatory bowel disease (IBD) patients.
METHODS: Thirteen patients with histologically proven radiation proctosigmoiditis, 32 patients with active ulcerative colitis (UC), 35 patients with Crohn's disease, and 15 normal subjects undergoing routine colonoscopy were included in the study. All patients underwent colonoscopy and mucosal biopsies were obtained from both diseased and normal-appearing areas. Mucosal levels of IL-1beta, IL-2, IL-6, and IL-8 were determined by solid-phase enzyme-linked immunosorbent assay (ELISA) using the Quantikine method (R&D Systems, Minneapolis, MN). All the data were statistically analyzed using Student's t test.
RESULTS: The mucosal levels of IL-2, IL-6, and IL-8 were significantly higher in both diseased segments (5.62 +/- 0.13, 1.60 +/- 0.31, and 21.45 +/- 4.03 pg/ml, respectively) and normal-appearing segments (3.83 +/- 0.78, 1.36 +/- 0.34, and 13.45 +/- 3.18 pg/mg) in the radiation proctitis group compared to those of normal control subjects (1.74 +/- 0.23, 0.67 +/- 0.09, and 4.99 +/- 1.39 pg/mg). These differences were statistically significant (p < 0.05). In the UC group, IL-1beta, IL-6, and IL-8 levels in diseased segments were 4.98 +/- 0.53, 2.22 +/- 0.28, and 88.85 +/- 8.05 pg/mg, respectively. In Crohn's disease patients, IL-1beta, IL-6, and IL-8 levels were 5.45 +/- 0.93, 2.88 +/- 0.58, and 61.68 +/- 10.02 pg/mg, respectively. All these levels were significantly higher (p < 0.05) compared with IL-1beta, IL-6, and IL-8 levels from normal segments of IBD patients. Compared with the radiation proctitis patients, the levels of IL-6 and IL-8 were significantly higher in the IBD group.
CONCLUSIONS: The mucosal levels of IL-2, IL-6, and IL-8 were significantly higher in both diseased and normal segments of colon in patients with radiation proctitis, compared with normal controls. Only IL-1beta levels were significantly higher in diseased segments, compared with endoscopically normal-appearing segments in radiation proctitis. These results indicate that there is a similarity in the activation of mucosal cytokines between IBD and radiation proctosigmoiditis. This may partly explain the beneficial effects of similar topical and systemic agents such as steroids and mesalamine compounds when used in radiation-induced proctosigmoiditis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811331     DOI: 10.1111/j.1572-0241.2000.02013.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  25 in total

1.  Recurrence of radiation enterocolitis within 1 year is predictive of 5-year mortality in surgical cases of radiation enterocolitis: our 18-year experience in a single center.

Authors:  Ming-Cheng Chen; Feng-Fan Chiang; Hwei-Ming Wang; Joe-Bin Chen; Te-Hsin Chao; Hsiu-Feng Ma
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

2.  Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity.

Authors:  Michael Pinkawa; Carolina Ribbing; Victoria Djukic; Jens Klotz; Richard Holy; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2015-05-26       Impact factor: 3.621

3.  Treatment of radiation-induced hemorrhagic gastritis with prednisolone: a case report.

Authors:  Lan Zhang; Xiao-Ying Xie; Yan Wang; Yan-Hong Wang; Yi Chen; Zheng-Gang Ren
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

4.  Mechanisms of transcriptional modulation of the human anion exchanger SLC26A3 gene expression by IFN-{gamma}.

Authors:  Seema Saksena; Amika Singla; Sonia Goyal; Shivani Katyal; Nikhil Bansal; Ravinder K Gill; Waddah A Alrefai; Krishnamurthy Ramaswamy; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-25       Impact factor: 4.052

5.  Ethyl pyruvate inhibits LPS induced IPEC-J2 inflammation and apoptosis through p38 and ERK1/2 pathways.

Authors:  Na Dong; Xinyao Xu; Chenyu Xue; Chensi Wang; Xinran Li; Chongpeng Bi; Anshan Shan
Journal:  Cell Cycle       Date:  2019-09-01       Impact factor: 4.534

6.  Lactobacillus acidophilus attenuates downregulation of DRA function and expression in inflammatory models.

Authors:  Varsha Singh; Anoop Kumar; Geetu Raheja; Arivarasu N Anbazhagan; Shubha Priyamvada; Seema Saksena; Muhammad Nauman Jhandier; Ravinder K Gill; Waddah A Alrefai; Alip Borthakur; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-07-24       Impact factor: 4.052

7.  Involvement of primary afferent nerves after abdominal irradiation: consequences on ileal contractile activity and inflammatory mediator release in the rat.

Authors:  Christine Linard; Christel Marquette; Carine Strup; Jocelyne Aigueperse; Denis Mathe
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

8.  Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in hemoglobin levels in primary radiotherapy for prostate cancer.

Authors:  Hans Christiansen; Bernhard Saile; Robert M Hermann; Margret Rave-Fränk; Andrea Hille; Heinz Schmidberger; Clemens F Hess; Giuliano Ramadori
Journal:  J Cancer Res Clin Oncol       Date:  2006-11-25       Impact factor: 4.553

9.  Recent advances in the management of radiation colitis.

Authors:  Jannis Kountouras; Christos Zavos
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

10.  Effect of Wumeiwan on cytokines TNF-alpha, IL-6, IL-8, IL-10 and expression of NF-kappaBp65 in rats with ulcerative colitis.

Authors:  Heng Fan; Lin Shen; Qing Tang; Pengcheng Xiong; Zhexing Shou; Yi Liao; Li Liang; Xiaoyan Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.